MTOR and neoplasm: In addition, using rapamycin to inhibit S6 phosphorylation, an mTOR downstream effector, can restore the PARPi sensitivity of resistant BC cells, and the combination of rapamycin and PARPi can obviously suppress BRCA1-deficient tumor growth in vivo (Sun et al., 2014).